Patients with severe tricuspid regurgitation may have adverse events in long run
Japan: In the long term, patients with severe tricuspid regurgitation (TR) may experience adverse events, a recent study featured in the Journal of the American Heart Association has shown.
A risk model based on renal or liver dysfunction, pulmonary hypertension, and left atrial enlargement revealed a graded rise in the risk of future adverse events.
Tricuspid regurgitation is a common echocardiographic finding, and it is seen in 70-90% of the general population. TR is believed to be a benign disease and is often asymptomatic and can be managed conservatively with treatments such as diuretic therapy. However, sometimes it can cause right‐sided heart failure and need a catheter or surgical intervention. Recent studies have shown that increased severity of TR was linked with higher mortality. However, the natural history and optimal interventional timing in patients with isolated severe TR have not been appropriately studied.
Against the above background, Naoki Nishiura from Kobe City Medical Center General Hospital in Kobe, Japan, and colleagues aimed to determine long-term clinical outcomes and risk factors linked with poor prognosis in isolated severe tricuspid regurgitation patients.
For this purpose, the researchers retrospectively reviewed successive transthoracic echocardiographic examinations in 2877 patients with isolated severe tricuspid regurgitation. Patients having significant left‐sided valve disease or repeated examinations were not included in the study.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.